Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Date:10/27/2008

CIMZIA(R) Data Shows Long-term Improvements in Productivity, Quality of

Life and Lessened Fatigue According to Studies Presented at American

College of Rheumatology (ACR) Annual Scientific Meeting

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced today results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. Results from the open-label extension study to RAPID 1 met both co-primary endpoints (American College of Rheumatology (ACR) 20 response(a) scores at Week 24 and change from baseline in modified Total Sharp Scores at Week 52). Results also showed that CIMZIA together with methotrexate (MTX) provided ACR 20 response as early as Week 1 with sustained long-term benefit in relieving symptoms of rheumatoid arthritis (RA) through 100 weeks.

Another analysis investigating the rapidity of response to CIMZIA as a monotherapy (FAST 4WARD) and together with MTX (RAPID 1) was presented at the meeting. Both studies met their primary endpoints (ACR20 response rate at Week 24) with clinical and statistical significance. The analysis presented showed that the response to CIMZIA treatment was rapid in both studies with more than a third (36.7 percent) of patients receiving CIMZIA as a monotherapy (FAST 4WARD) and nearly a quarter (22.9 percent) of patients receiving CIMZIA together with MTX (RAPID 1) achieving an ACR20 response within one week, both significantly different from placebo. ACR20 response rates peaked at Week 12 in both studies and were sustained until the end of the studies (Week 24 in FAST 4WARD; Week 52 in RAPID 1).

"The data show that treatment with CIMZIA in clinical trials produced a fast and clinically meaningful effect for RA patients over an extended period of time," said Michael Schiff, M.D., study investigator and Clinical Pro
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
2. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
3. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
6. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
7. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
8. Fralex provides update on timing of interim analysis results
9. Vanda Pharmaceuticals Provides Update on Iloperidone
10. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
(Date:5/6/2015)... , May 6, 2015 ... therapy with dolutegravir and rilpivirine   ... a Phase III clinical trial programme to evaluate ... rilpivirine (Edurant® [1] ) as maintenance therapy for ... comprises two replicate studies evaluating 48 week viral ...
(Date:5/6/2015)... Woodford Patient Capital Trust ... and the Bill & Melinda Gates Foundation to ... leading monoclonal antibody biopharmaceutical company, announced today that ... to complete a US$90 million Series B financing. ... Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin Corporation ...
Breaking Medicine Technology:Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4
(Date:5/6/2015)... Norcross, GA (PRWEB) May 06, 2015 ... has chosen Hexagon Geospatial technology to manage and distribute ... , Australia is one of the driest continents on ... supply through times of drought and erratic seasonal rainfalls ... water supply solutions. , Water NSW manages raw water ...
(Date:5/6/2015)... Mateo, Calif. (PRWEB) May 06, 2015 ... SafeMonk today announced a strategic partnership to help ... the cloud. The two industry-leading companies are teaming up ... platform. , “We’re thrilled to welcome SafeMonk ... to us that the people behind SafeMonk, the global ...
(Date:5/6/2015)... 2015 National Physical Fitness and Sports ... within the U.S. Department of Health and Human Services ... Fitness and Sports Month. It is dedicated to ... to health. Throughout the month of May, Americans ... fit. , The HHS details the benefits of regular ...
(Date:5/6/2015)... May 06, 2015 Most people in the ... nursing or other care after age 65. But less than ... for it or even talking about it, reports the May ... people risk two problems. One is losing control over the ... families," says Dr. David Grabowski, a professor of health care ...
(Date:5/6/2015)... Herndon, VA (PRWEB) May 06, 2015 ... its CIT GAP Funds has invested in e-Kare, Inc. ... speeds the assessment and monitoring of chronic wounds. , ... burn, and complex surgical wounds that affect over 6.5 ... in 2013 as a spin-off enterprise from the Children’s ...
Breaking Medicine News(10 mins):Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 2Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2Health News:CIT GAP Funds Invests in e-Kare 2Health News:CIT GAP Funds Invests in e-Kare 3
... 20 MCG Capital,Corporation (Nasdaq: MCGC ) today ... support the acquisition of Gould & Lamb, LLC by ... services company that is unique to,the workers, compensation industry. ... the workers, compensation industry,since 2001. Having completed in excess ...
... Hospitals are dangerous,places and the danger is even greater ... temps are relied on more than usual, and the ... McCaughey, Ph.D., Chairman of the Committee to Reduce Infection,Deaths, ... that hospital staff are eager to improve your safety ...
... DRAXIMAGE strong competitive position in ... Dec. 20 /PRNewswire-FirstCall/ - DRAXIMAGE, the,radiopharmaceutical division ... has appointed GE Healthcare, an industry leader ... DRAXIMAGE(R) Sestamibi in the United,States. DRAXIMAGE(R) Sestamibi ...
... 10 Law Offices of Howard G. Smith,announces ... be a lead plaintiff in,the securities class action ... common stock of Threshold Pharmaceuticals, Inc. ("Threshold,Pharmaceuticals" or ... 2005,and July 14, 2006 (the "Class Period"), including ...
... XCPT, LLC has entered into a,representation agreement ... dentists throughout the world. XCPT,s software is ... recognizing the importance of visual learning during,treatment planning. ... step of the,dental treatment process as the clinician ...
... Calif., Aug. 10 Mike Huckabee,will be the keynote ... at the Disneyland(R) Hotel in Anaheim, CA. The,event will ... "We are very honored to have a national ... who understands the importance of,Christian higher education as our ...
Cached Medicine News:Health News:MCG Capital Invests in Gould & Lamb 2Health News:How to Survive an Unexpected Trip to the Hospital During Christmas and New Years 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 4Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 5Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 6Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 7Health News:Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc. 2Health News:XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM) 2Health News:Presidential Candidate and Former Arkansas Governor Mike Huckabee to Be Keynote Speaker for Hope International University's 'Celebrate Hope' Dinner at Disneyland(R) Hotel 2
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
The perfect tool to prepare for in-service or licensing exams, for recertification, or for use as a clinical refresher....
... Med TruFlow™ Oxygen flowmeter with a Lexan®inner ... covering calibration and manufacturing defects. A wide ... most needs. Also available with all popular ... take-off and double unit configurations. Our extra ...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
Medicine Products: